New Zealand feature: primary industry backs NZ biotech
12 July, 2002 by Melissa TrudingerIf biotechnology is as old as agriculture, then biotechnology in New Zealand has been around for as long as the nation. New Zealand is a country that relies on its strengths in its primary industries - dairying and sheep, horticulture and forestry.
Amrad abandons hep B compound after poor trials
11 July, 2002 by Tanya HollisAmrad Corporation's horror year plumbed new depths today when the company revealed poor results had led it to abandon its chronic hepatitis B compound.
Compumedics revises revenue figure, shares drop
11 July, 2002 by Tanya HollisSleep device developer Compumedics has flagged a 10 per cent reduction in its forecast sales for the year, triggering a share price slide.
Which genes make the best baked dinner?
11 July, 2002 by Melissa TrudingerA project at the South Australian Research and Development Institute (SARDI) is focusing on the qualities that make lamb tender and tasty.
Going for funding? Get a cash parachute, says Alchemia CEO
11 July, 2002 by Pete YoungBiotech companies in the midst of new funding rounds should build an extra cushion of cash into their requests, warns Alchemia CEO Tracie Ramsdale.
Strong US sales for Genetic Solutions
10 July, 2002 by Pete YoungTwo ex-CSIRO scientists who have spent four years quietly commercialising Australian expertise in livestock DNA testing are in the midst of a US sales boom.
Peptech earns TNF patent protection in US
10 July, 2002 by Tanya HollisSydney-based biotech Peptech has gained United States patent protection for its tumour necrotising factor (TNF) antibodies, priming the company for its next growth phase.
EQiTX sets itself up for biotechnology
09 July, 2002 by Tanya HollisA Western Australian oil and metal exploration company has gathered some of the top names in Australian science as it moves towards rebirth as a biotech.
BioProspect's Japanese Qcide deal
09 July, 2002 by Tanya HollisNatural insecticide developer BioProspect has reached a second deal over rights to test its new product.
Cone snail venom could treat chronic pain
08 July, 2002 by Melissa TrudingerA novel compound from the venom of a cone shell marine snail found on the Great Barrier Reef may have a use as a drug to treat chronic pain, according to scientists from the University of Melbourne and the National Ageing Research Institute.
BresaGen halts study on leukaemia drug
08 July, 2002 by Tanya HollisA leukaemia drug developed by Adelaide biotech BresaGen will go back to the drawing board after it was found not to be as effective as previously thought against one form of the disease.
Cardia subsidiary Bioglobal buys blowfly IP
08 July, 2002 by Melissa TrudingerCardia Technologies subsidiary Bioglobal has bought intellectual property from Queensland's Department of Primary Industries relating to blowfly attract and kill technology.
Give it a myth: the big assumptions about GM
05 July, 2002 by Melissa TrudingerSeveral myths, misconceptions and assumptions about genetically modified organisms and food have made their way into the public arena. What doesn't help the average punter to get a grip on the science is that there are huge swathes of information available, from scientists, policy-makers, lobbyists and industry. And for every opinion exists its opposite.
New research eases strain on artificial muscle
05 July, 2002 by Tanya HollisAustralian researchers have created salt-based liquids that improve the performance of artificial muscle by thousands of times.
Shareholders back MicroMedical name change
05 July, 2002 by Tanya HollisA proposed name change for artificial heart developer MicroMedical Industries has gained the backing of nearly all its shareholders.
